Monopar Therapeutics MNPR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's cash & equivalents?
- Monopar Therapeutics (MNPR) reported cash & equivalents of $52.54M in Q1 2026.
- How has Monopar Therapeutics's cash & equivalents changed year-over-year?
- Monopar Therapeutics's cash & equivalents increased by 32.3% year-over-year, from $39.71M to $52.54M.
- What is the long-term trend for Monopar Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Monopar Therapeutics's cash & equivalents has grown at a 30.1% compound annual growth rate (CAGR), from $16.61M to $61.83M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.